Navigation Links
Pharmacyclics Reports Fiscal 2012 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 53rd American Society of Hematology Annual Meeting
Date:11/7/2011

ns non-GAAP financial measures, including operating and other expenses adjusted to exclude certain non-cash and non-recurring expenses. These measures are not in accordance with, or an alternative to generally accepted accounting principles, or GAAP, and may be different from non-GAAP financial measures used by other companies. The items included in GAAP presentations but excluded for purposes of determining non-GAAP financial measures for the periods presented in this press release are employee related non-cash expenses. We believe the presentation of non-GAAP financial measures provides useful information to management and investors regarding various financial and business trends relating to our financial condition and results of operations. When GAAP financial measures are viewed in conjunction with non-GAAP financial measures, investors are provided with a more meaningful understanding of our ongoing operating performance. In addition, these non-GAAP financial measures are among those indicators we use as a basis for evaluating operational performance, allocating resources and planning and forecasting future periods. Non-GAAP financial measures are not intended to be considered in isolation or as a substitute for GAAP financial measures. To the extent this release contains historical non-GAAP financial measures, we have also provided corresponding GAAP financial measures for comparative purposes. Reconciliation between certain GAAP and non-GAAP measures is provided below.

About PharmacyclicsPharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medial healthcare needs; and to identify promising produc
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Pharmacyclics Reports Financial Results and Recent Developments for Fiscal Year and Fourth Quarter 2011 - Conference Call Set for Today at 4:30 PM EDT
2. Pharmacyclics Announces Date of Fiscal Year End 2011 Financial Results and Conference Call
3. Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765
4. Pharmacyclics Announces Oral Presentations and Clinical Update at Upcoming Medical Meetings
5. Pharmacyclics to Announce Third Quarter Fiscal 2011 Results and Host a Conference Call on May 4, 2011
6. Pharmacyclics to Announce Second Quarter Fiscal 2011 Results and Host a Conference Call on February 4, 2011
7. Pharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human Btk-Inhibitor PCI-32765
8. Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765
9. Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010
10. Pharmacyclics Announces Date of Fiscal Year End 2010 Financial Results and Conference Call and Presentation at Stifel Nicolaus Healthcare Conference
11. Pharmacyclics to Present at Bank of America Merrill Lynch Healthcare Conference and MDB Bright Lights Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... FRANKLIN, Mass. , Aug. 27, 2015 /PRNewswire/ ... in the KSSTA Knee Journal, compared the Arthrosurface ... "inlay" Arthroplasty design, versus an "onlay" design implant ... showed similar improvements in function and pain scores, ... showed progression of osteoarthritis (OA). However, 53% of ...
(Date:8/27/2015)... According to a new market research report "Medical Lifting ... ), Material (Nylon, Padded, Canvas), Usage Type (Disposable, Reusable), End User ... Medical Lifting Sling Market is poised to reach USD 706.0 Million ... of 11.4 % from 2015 to 2020. , ... ables and 65 F igures ...
(Date:8/27/2015)... BIRMINGHAM, Ala. , Aug. 27, 2015 ... Integrated Outpatient Pharmacy Provider (IOPP™) is expanding ... launch of a medication-focused transition of care ... program, named "RxCare Management," provides hospitals with ... improve hospital performance measures that have been ...
Breaking Medicine Technology:Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 2Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 3Medical Lifting Sling Market Worth USD 706.0 Million by 2020 2Medical Lifting Sling Market Worth USD 706.0 Million by 2020 3Medical Lifting Sling Market Worth USD 706.0 Million by 2020 4Rx Care Management by Proxsys Rx - Transition of Care Technology Helps Prevent Hospital Medication Errors 2
... 2011 Nektar Therapeutics (Nasdaq: NKTR ) ... 2 clinical study of NKTR-102 in patients with metastatic ... Cancer Symposium in San Francisco, California.  NKTR-102 is a ... conjugate technology, and is being developed in multiple tumor ...
... The Board of the European Fine Chemicals ... to ratify the proposal of the US Food and Drug ... the help of EFCG and US industry representatives, to deliver ... (GDUFA). GDUFA requires the FDA to commit to ...
Cached Medicine Technology:Positive Results from Phase 2 Clinical Study of NKTR-102 in Metastatic Breast Cancer Presented in Oral Session at the ASCO 2011 Breast Cancer Symposium 2Positive Results from Phase 2 Clinical Study of NKTR-102 in Metastatic Breast Cancer Presented in Oral Session at the ASCO 2011 Breast Cancer Symposium 3Positive Results from Phase 2 Clinical Study of NKTR-102 in Metastatic Breast Cancer Presented in Oral Session at the ASCO 2011 Breast Cancer Symposium 4Positive Results from Phase 2 Clinical Study of NKTR-102 in Metastatic Breast Cancer Presented in Oral Session at the ASCO 2011 Breast Cancer Symposium 5Positive Results from Phase 2 Clinical Study of NKTR-102 in Metastatic Breast Cancer Presented in Oral Session at the ASCO 2011 Breast Cancer Symposium 6European Fine Chemicals Group Ratifies FDA's Proposed Generic Drug User Fees Act (GDUFA) 2
(Date:8/28/2015)... ... August 28, 2015 , ... “ Frequentz ” was ... the latest and coolest applications on the market for iOS, Android, and Windows. Joe ... with viewers how this software allows businesses to track product movement from beginning to ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... Veterans Award, honoring military veterans leading in business. Mr. Troy Mizell, Chairman ... , The inaugural Nashville Business Journal's 2015 Veterans Awards will recognize Nashville military ...
(Date:8/28/2015)... ... ... The Quatela Center for Plastic Surgery is excited to bring patients the ... by the Food and Drug Administration to eliminate submental fat, also known as the ... are among the premier cosmetic surgeons in Rochester to offer this innovative procedure.     , ...
(Date:8/28/2015)... La Mirada, Ca (PRWEB) , ... August 28, ... ... are now administering medical evaluations for those seeking to go deep sea diving. ... pressure, possible oxygen toxicity, and decompression sickness; for these reasons, it is vital ...
(Date:8/28/2015)... ... August 28, 2015 , ... United Benefit ... welcome TJS Insurance Group as its newest Partner Firm. Founded in 1924 and ... keeps them focused on their goals. Within the past 10 years, TJS Insurance ...
Breaking Medicine News(10 mins):Health News:Track Product Movement from Beginning to End with Frequentz 2Health News:MyGenetx Board Member Receives Veterans Award 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 3Health News:Healthpointe Now Offering Scuba Physicals 2Health News:TJS Insurance Group Is Latest Partner Firm To Join United Benefit Advisors 2Health News:TJS Insurance Group Is Latest Partner Firm To Join United Benefit Advisors 3
... is observed that breathing oxygen may cause some harm to ... beds of people //with severe lung or heart disease.Oxygen supports ... enough through the blood. But oxygen is often given inappropriately. ... 'breathe of life'. ,A study by researchers at New ...
... observed that approximately two thirds of teenage boys and ... suffer from at least// one psychiatric disorder. In ... evaluated by researchers before they were admitted to a ... interviewed the juvenile teens in order to track the ...
... Researchers have found that two types of scan are ... of ovarian cancer within the abdominal cavity. Positron emission ... of tumour tissue, while computed tomography (CT) is good ... School have found that combining the two detects ovarian ...
... an artificial disc to replace damaged spinal discs has successfully ... by discs of cartilage which serve as a cushion between ... two spinal bones may grind together, giving rise to acute ... disc is to remove it and fuse the two spinal ...
... with severe respiratory disease can walk further, and are less ... is key to pulmonary// rehabilitation in people who develop severe ... can walk in a fixed time and this helps them ... Ohio State University now report on the beneficial effect of ...
... coping style helps women to deal positively with breast cancer. ... difference in the fight against cancer. Researchers in the US ... stress, mental outlook and coping style are all relevant to ... ,They found that up to 44 per cent of ...
Cached Medicine News:
... The BiPAP Pro with Bi-Flex bi-level system, ... that the BiPAP Pro takes to change ... Digital Auto-Trak Sensitivity™ which automatically triggers the ... pressures based on the patients breathing rhythm. ...
... Electrophoresis System (PGGE) is designed to ... density lipoproteins (LDL) and high density ... using nondenaturing pore gradient gel electrophoresis. ... short DNA sequencing runs. Temperature control ...
This control is intended for monitoring cell counts in patient cerebrospinal fluid samples, performed manually using a hemocytometer. Spinalscopics is fortified to target levels with purified chemica...
... Suitable for use with Leica ... bilirubinometers (pediatric) and all automated ... including Aeroset, AU Series, Cobas, ... These controls contain purified bilirubin ...
Medicine Products: